Health Winners & Losers: Thermage
Thursday proved to be another droopy day for health stocks, as news kept on the light side and investor sentiment continued to mimic the broader markets.
The Nasdaq and Amex biotechnology indices were down 0.8% and 0.7%, respectively. The Amex Pharmaceutical Index was off by just 0.07%.
Thermage (THRM) soared Thursday after the company said it received a revised unsolicited bid from a third party, putting its pending acquisition of Reliant Technologies in doubt.Thermage, which makes devices for wrinkle treatments, would receive $5.50 a share in cash or a combination of cash and stock in the third-party bid. The company, which in July that it would buy the laser skin resurfacing company Reliant Technologies for $87.5 million in cash and stock, said its board will consider the proposal and respond in due course. If it accepts the bid, it would scrap the Reliant deal. Thermage shares rose $1.32, or 43.7%, to $4.34. In clinical news, Bayer and Onyx (ONXX) said Thursday that they have begun enrolling patients in a late-stage study, dubbed STORM, on Nexavar as an adjuvant treatment for prevention of recurrence of hepatocellular carcinoma, or primary liver cancer, following surgery or local radiation. The company said the Food and Drug Administration has completed a special protocol assessment (SPA) -- an agreement on the design and size of a trial meant to be the basis for a new drug application -- for the STORM trial. Onyx shares, however, were off by 52 cents, or 1.2%, at $41.57. In analyst actions, Lazard upgraded ArthroCare (ARTC) to buy from hold, with a $38 price target. Its shares were up $1.20, or 4.8%, at $26.37. Also, Leerink Swann initiated coverage of Jazz Pharmaceuticals (JAZZ) with a market perform rating. Jazz shares were down 36 cents, or 4.5%, at $7.71.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV